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Background: The safety of long-acting b2-agonists (LABAs) in asthma is debated. This study
examined the safety of the inhaled corticosteroid (ICS)/LABA combination budesonide/formo-
terol dry powder inhaler used as maintenance and reliever therapy versus combination treat-
ments based on guideline recommendations.
Methods: Safety data from six double-blind, randomised clinical trials (RCTs) in asthma where
budesonide/formoterol was used as maintenance and reliever therapy for at least 6 months
were reviewed (NZ 14 346). All-cause mortality and asthma-related serious adverse events
(SAEs) (co-primary endpoints), overall and cardiac SAEs, and discontinuations due to adverse
events (DAEs) were assessed. Estimated ManteleHaenszel (MH) relative risks (RR) with this
regimen versus comparators were calculated.
Results: There was no increase in all-cause mortality with budesonide/formoterol mainte-
nance and reliever therapy (four deaths [0.07%] versus nine [0.10%]; pooled MH RR 0.70, 95%
confidence interval [CI] 0.21e2.30). Asthma-related SAEs were reduced with budesonide/for-
moterol maintenance and reliever therapy: 41 (0.73%) versus 121 (1.38%); pooled MH RR 0.59,
95% CI 0.42e0.85. All-cause and asthma-related DAEs were also reduced with budesonide/for-
moterol maintenance and reliever therapy: pooled MH RR 0.60 (95% CI 0.46e0.79) and 0.43
(0.28e0.68), respectively. Overall and cardiac-related SAEs were comparable between treat-
ment groups: pooled MH RR 0.96 (95% CI 0.82e1.14) and 1.26 (0.72e2.22), respectively.
Conclusion: Budesonide/formoterol dry powder inhaler maintenance and reliever therapy was
well tolerated in RCTs versus fixed-dose alternatives and not associated with increased risk of
death or cardiac-related SAEs and DAEs, and asthma-related SAEs and DAEs were significantly
reduced. Given the limitations of RCTs, particularly exclusion of patients with co-morbidities,
ongoing surveillance is appropriate.
ª 2009 Elsevier Ltd. All rights reserved.5 522 1155x33286; fax: þ1 905 521 6132.
.ca (M.R. Sears).
9 Elsevier Ltd. All rights reserved.
Safety of symbicort maintenance and reliever therapy 1961Introduction debated.
18e20 The use of LABAs without concomitant ICS isGuidelines for management of asthma focus on the goals of
overall asthma control, i.e. achieving current control and
reducing future risks. Optimal current control is charac-
terised by infrequent symptoms, only occasional rescue
bronchodilator use, lung function at or near normal stable
levels, and normal physical activity levels. Reduced future
risk is characterised by preventing exacerbations, lung
function decline and medication adverse effects.1e3 The
recent Global Initiative for Asthma (GINA) guidelines use
the characteristics of current control noted above to clas-
sify patients as having Controlled, Partly Controlled or
Uncontrolled asthma. Addition of a long-acting b2-agonist
(LABA) is recommended if patients are inadequately
controlled on low to moderate doses of inhaled cortico-
steroid (ICS) alone.3 Trials of combination therapy with
a LABA and an ICS in separate inhalers or, more recently, in
fixed-dose formulations of budesonide/formoterol (Symbi-
cort) or salmeterol/fluticasone (Seretide and Advair)
have consistently reported increased proportions of
patients with good asthma control and reduced future risk
of exacerbations compared with increasing the dose of ICS
alone.4e6
A more recent development for employing combination
ICS/LABA treatment (outside of the U.S.) is the use of
budesonide/formoterol dry powder inhaler (DPI) (Turbu-
halerc) as both maintenance and reliever therapy (Sym-
bicort SMARTd). This strategy, which is now included in
the GINA treatment guidelines for asthma, uses a fixed-dose
combination of budesonide and formoterol for maintenance
therapy supplemented with additional doses of the same
combination rather than a separate short-acting b2-agonist
(SABA) when reliever therapy is needed. The therapeutic
concept is that this strategy provides additional anti-
inflammatory therapy when symptoms begin to develop,
thus further reducing exacerbations, eliminates the need
for a separate SABA inhaler7 and may allow lower doses of
ICS and LABA during periods when asthma is stable.
Six large, double-blind, randomised clinical trials
involving more than 14 000 asthma patients have shown
that budesonide/formoterol maintenance and reliever
therapy reduces severe asthma exacerbations compared
with higher maintenance doses of ICS6,8,9 or combinations
of higher-dose ICS with LABA10,11 or same-dose ICS with
LABA,6,12 all used with SABA as needed for relief. In addi-
tion to the gains in efficacy, health economic analyses have
shown beneficial results for budesonide/formoterol main-
tenance and reliever therapy.13e15 Recently, several open-
label studies of budesonide/formoterol maintenance and
reliever therapy that more closely mirror ‘real-world’
settings16,17 have reported that this strategy improved
asthma control and was associated with fewer exacerba-
tions compared with other guideline-based regimens of
conventional best practice selected by the patient’s
physician.
During recent years, the relationship between the use of
LABAs and asthma mortality and morbidity has been heavilyc Turbuhaler is a trademark owned by AstraZeneca. The dry powder
d Symbicort SMART is a trademark owned by AstraZeneca. The Symbof concern, as studies report increased asthma-related
mortality and serious adverse events (SAEs)20 with LABA
monotherapy, most probably as a consequence of the
masking of, and risk resulting from the undertreatment of,
underlying inflammation.21 International guidelines, and
a recent FDA review panel, recommend that LABAs should
only be used in combination with an appropriate dose of
ICS.3 The strategy of using budesonide/formoterol as both
maintenance and reliever therapy obviates the potential
risk of LABA monotherapy in that ICS is delivered with each
dose of formoterol, and so should improve the benefit/risk
ratio of LABA therapy.
We have reviewed the safety data reported in clinical
trials in adolescents and adults with asthma in six double-
blind trials6,8e12 in which budesonide/formoterol DPI was
used as maintenance and reliever therapy. The incidence of
mortality and morbidity was compared with that observed
for a range of comparator treatments including budeso-
nide, budesonide/formoterol or salmeterol/fluticasone
used as maintenance therapy combined with a SABA, or in
one trial formoterol,12 as reliever therapy. As a supple-
mentary analysis, data from seven open-label trials were
analysed separately. The purpose of this paper is to
examine the safety of a new treatment regimen versus
standard guideline-based treatments for asthma.
Methods
Data source
All double-blind AstraZeneca trials in patients with asthma
involving the use of budesonide/formoterol as maintenance
and reliever therapy for at least 6 months were identified
through the company database. Of 14 346 patients rando-
mised into the six trials, 5584 used budesonide/formoterol
as maintenance and reliever therapy and 8762 used
comparator treatments, namely guideline-based treatment
regimens for moderate to severe, persistent asthma,
including use of regular budesonide, budesonide/for-
moterol or salmeterol/fluticasone, all with a SABA or for-
moterol as reliever medication.6,8e12 Five of the trials
enrolled patients aged 12e89 years (although four patients
aged 11 years were enrolled erroneously) and one trial6 also
enrolled children aged 4e11 years. The mean age was 39.4
years (range 4e89 years), 5921 patients (41%) were male
and the distribution by ethnic origin was 74% Caucasian,
17% Oriental, 1% Black and 8% of other race.
Data from seven open-label trials with 9890 patients
were analysed separately.
Outcome events
All-cause mortality and asthma-related SAEs were co-
primary endpoints. Secondary outcomes were overall SAEs,
cardiac-related SAEs, discontinuations due to adverse
events (DAEs), and asthma-related and cardiac-relatedformulation Turbuhaler is currently not approved in the U.S.
icort SMART posology is currently not approved in the U.S.
1962 M.R. Sears, F. RadnerDAEs. All these events were evaluated at the time by the
investigators involved in each study and prior to unblinding.
All fatalities in all trials were reassessed by the present
authors and categorised as asthma-related, cardiac-related
or due to other reasons. Adverse events commonly
observed with b2-agonists and ICS were recorded in all
studies and have been summarised and presented as addi-
tional safety information.
Asthma-related events were defined as any event coded
to the preferred terms asthma, status asthmaticus or
bronchospasm according to the Medical Dictionary for
Regulatory Activities (MedDRA) version 8.0. In addition, one
death in the trial by Kuna et al.,11 coded by the trial
investigator as due to respiratory failure, was considered by
the current authors as asthma-related. Cardiac-related
events were defined as any event coded using MedDRA v 8.0
according to the terms in Table E1, on-line supplement.
SAEs (asthma- and cardiac-related) were defined using
the International Conference on Harmonisation recommen-
dations, i.e. any adverse event that was immediately life
threatening, required inpatient hospitalisation or prolonga-
tion of existing hospitalisation, resulted in persistent or
significant disability or incapacity, was a congenital abnor-
mality/birth defect or was an important medical event that
may jeopardise the subject or require medical intervention
to prevent one of the outcomes listed above.
Events were counted as the number of patients reporting
at least one such event. When multiple events were
recorded, a patient was counted once for each group of
adverse events. Thus, a patient reporting both angina
pectoris and hypertension would be counted once in the
group of cardiac-related events, while a patient reporting
two asthma attacks and one angina pectoris would be
counted once among the asthma-related events and once
among the cardiac-related events.
Deaths and DAEs were represented by the event result-
ing in the death or discontinuation. Deaths during treat-
ment were included among the SAEs, DAEs and adverse
events. For SAEs and adverse events, multiple occurrences
of the same event were counted as the first incidence of
the event.
Data analyses
For each patient, the person-time of participation in the
trial was measured and cumulated to obtain person-years
of exposure. The rates of events were expressed per 1000
treatment years (TTY) computed for each treatment group,
ignoring the very small number of patients with multiple
events of the same type. Due to the very small number of
deaths, statistical methodology was only applied to all-
cause mortality, while categorised deaths are presented
descriptively. Overall relative risk (RR) was analysed using
a stratified ManteleHaenszel (MH) approach adjusted for
treatment exposure, which allowed for possible differences
between trials, thereby reducing bias. This provided the
pooled MH RR and 95% confidence interval (CI) for each
outcome event. For individual studies, a descriptive 95%
credibility interval for the RR was provided using the
method of Barker and Cadwell with an uninformative
uniform prior; the median of the posterior distribution was
used to provide a point estimate for the RR.22 TheseBayesian risk estimates and credibility intervals are pre-
sented in Forest-plots, together with the pooled MH RR and
its 95% CI for each outcome event. In Table E2 in the on-line
supplement, the MH RR and 95% CI, when calculable, are
presented for each outcome event for each trial. In addi-
tion, the reporting of asthma-related SAEs over time was
analysed using a Cox regression model, stratified by study,
and displayed using a KaplaneMeier survival curve.
Because adverse events may be greater among older
subjects, a sub-group analysis was performed restricted to
those aged 50 years and older.
For RRs, differences were considered statistically
significant when the 95% CI excluded 1.00.
Formoterol doses are expressed as delivered doses.
Formoterol delivered doses of 9 mg and 18 mg correspond to
metered doses of 12 mg and 24 mg, respectively.
Results
Number of trials and patients
Details of the clinical trials included in the safety database,
comparator treatments in each of the trials, corresponding
treatment years, daily delivered doses of maintenance ICS/
LABA therapy, and percentage of days with at least four as-
needed inhalations are shown in Table 1.6,8e12 Because
there were multiple arms in some of the clinical trials, the
number of patients in the comparator groups (nZ 8762)
exceed those in the budesonide/formoterol maintenance
and reliever therapy groups (nZ 5584). The distribution of
patients by number of trials and comparator treatments
and the exposure time is shown in Fig. 1. Total exposure
time for the budesonide/formoterol maintenance and
reliever therapy group was 3.94 TTY versus 6.29 TTY for the
combined comparator group.
Deaths
Death was reported for four patients (0.07%) in the budeso-
nide/formoterol maintenance and reliever therapy arm of
the study and for nine controls (0.10%); nonewere attributed
by the investigator to the study medication. Two were
deemed to be asthma-related (one in each group) and four
deaths cardiac-related (all in the comparator group). There
was no increase in the risk for any specific type of death with
budesonide/formoterol maintenance and reliever therapy
compared with alternative treatments (Table 2). The pooled
exposure-adjustedMHRR for all-causedeathwas 0.70 (95%CI
0.21e2.30) as shown in Table 2 and Fig. 2. (Numeric data for
RRs and 95% CIs for all outcome variables per trial are pre-
sented in Table E2 in the on-line supplement.)
Asthma-related serious adverse events
Asthma-related SAEs were significantly reduced with
budesonide/formoterol maintenance and reliever therapy
compared with comparator therapy: 41 (0.73%) versus 121
(1.38%); pooled MH RR 0.59, 95% CI 0.42e0.85 (Table 3 and
Fig. 2).
KaplaneMeier survival curves indicated a clear separation
between treatment groups and a prolonged time to the event
Table 1 Clinical trial design and patient numbers contributing to analyses.
Study Duration
(months)
BUD/FORM
maintenance
and reliever
therapy
Comparators BUD/FORM maintenance and reliever therapy Comparators with daily delivered dose plus as-needed medication
Number of patients
(exposure in TTY)
Daily delivered
dose by protocol
(+ BUD/FORM prn)
Average
daily dose of
FORM
Days with at least
four as-needed
inhalations (%)a
BUD (+ TERB prn) BUD/FORM SAL/FLU
(+ SALB prn)
Scicchitano
20049
12 947 (0.85) 943 (0.83) 320/9 ~ 13 3 640
O’Byrne
20056
12 922 (0.84) 1831 (1.64) 160/9 (80/4.5)b ~ 13 3 640 160/9b + TERB prn
Rabe
2006A8
6 354 (0.17) 342 (0.16) 160/9 ~ 13 4 320
Rabe
2006B12
12 1107 (1.03) 2275 (2.10) 320/9 ~ 13 6 320/9 + TERB prn
320/9 + FORM prn
Kuna
200711
6 1103 (0.50) 2218 (1.00) 320/9 ~ 13 7 640/18 + TERB prn 100/500
Bousquet
200710
6 1151 (0.55) 1153 (0.54) 640/18 ~ 23 7 100/1000
TOTAL 5584 (3.94) 8762 (6.29)
BUD/FORMZ budesonide/formoterol; SAL/FLUZ salmeterol/fluticasone; TERBZ terbutaline; FORMZ formoterol; SALBZ salbutamol; prnZ as needed; TTYZ 1000 treatment years.
All doses are expressed as total daily doses in mg. All trials were double blind.
a Four as-needed inhalations results in a dose per day of 27 mg of formoterol for the first five trials and of 36 mg in the trial by Bousquet et al.
b Patients aged 4e11 years used half the maintenance medication.
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Full dataset: 6 trials
Randomised patients: 
n = 14 346
Total exposure: 
10.22 TTY
Treatment with budesonide/ 
formoterol maintenance and 
reliever therapy
Randomised patients: 
n = 5584 
Total exposure: 3.94 TTY
Treatment with comparators
Randomised patients: 
n = 8762
Total exposure: 
6.29 TTY
Budesonide plus SABA prn
3 trials
Randomised patients: n = 2210 
Total exposure: 1.82 TTY
Budesonide/formoterol plus SABA prn
3 trials
Randomised patients: n = 3143 
Total exposure: 2.35 TTY
Salmeterol/fluticasone plus SABA prn
2 trials
Randomised patients: n = 2272 
Total exposure: 1.05 TTY
Budesonide/formoterol plus formoterol prn
1 trial
Randomised patients: n = 1137 
Total exposure: 1.06 TTY
Figure 1 Flow-chart of randomised patients. prn Z as needed; SABA Z short-acting b2-agonist; TTY Z 1000 treatment years.
1964 M.R. Sears, F. Radnerin the budesonide/formoterol maintenance and reliever
therapy group compared with the comparator group (Fig. 3).
According to a log-rank test, stratified by study, the risk at
any particular time point was lower in the budesonide/for-
moterol maintenance and reliever therapy group compared
with the comparator group (pZ 0.004). In a Cox regression
model, also stratified by study, the hazard ratio was esti-
mated as 0.59 (95% CI 0.42e0.85, pZ 0.004), corresponding
to a 41% lower riskwith budesonide/formoterolmaintenance
and reliever therapy compared with comparator treatment
at a particular time point during the follow-up.
Cardiac-related and other serious adverse events
The reporting of cardiac-related SAEs was low in both treat-
ment groups with a numerically higher rate with budesonide/
formoterol maintenance and reliever therapy: 23 (0.41%)
versus 27 (0.31%), yielding a pooled MH RR of 1.26 and a 95% CI
of 0.72e2.22. Overall reporting of SAEs due to any cause was
similar between the treatment groups, 4.2% and 4.5% respec-
tively, with a pooled MH RR close to 1 (Table 3 and Fig. 4).
Discontinuations due to adverse events
All-cause DAEs and asthma-related DAEs were reduced with
budesonide/formoterol maintenance and reliever therapy
compared with alternative treatments: pooled MH RR 0.60
(95% CI 0.46e0.79) and 0.43 (0.28e0.68), respectively.Table 2 Rates and ratios of cause-specific death across six ran
BUD/FORM maintenance and reliever ther
exposureZ 3.94 TTY
Deaths (%) Rate per TTY
Asthma-related death 1 (0.02) 0.25
Cardiac-related death 0 0
Other deaths 3 (0.05) 0.76
Total deaths 4 (0.07) 1.02
BUD/FORMZ budesonide/formoterol; CI = confidence interval; RR =
a ManteleHaenszel relative risk for budesonide/formoterol maintenCardiac-related DAEs were numerically but not statistically
significantly lower among patients in the budesonide/for-
moterol maintenance and reliever therapy group: 8 (0.14%)
versus 15 (0.17%); MH RR 0.73 (95% CI 0.30e1.73) (Table 3
and Fig. 4).
Adverse events commonly observed with
b2-agonists or inhaled corticosteroid therapy
There were no notable differences observed between the
two treatment groups with regard to adverse events
commonly observedwithb2-agonists or ICS therapy (Table 4).
Results versus the individual comparators
As a sensitivity analysis, the incidence of all endpoints was
stratified by type of comparator. Thus, the budesonide/
formoterol maintenance and reliever therapy treatment
arms from the three trials with a budesonide plus SABA as-
needed treatment arm6,8,9 were combined to give 2223
patients on budesonide/formoterol maintenance and
reliever therapy versus 2210 on budesonide plus SABA as
needed. Similar groupings were made for comparisons with
budesonide/formoterol plus SABA as needed8,11,12 (3132
patients versus 3143 patients), budesonide/formoterol plus
formoterol as needed12 (1107 versus 1137 patients) and
salmeterol/fluticasone plus SABA as needed10,11 (2254
versus 2272 patients). For all-cause mortality, the numberdomised controlled trials.
apy: NZ 5584; Comparators: NZ 8762;
exposureZ 6.29 TTY
RR (95% CI)a
Deaths (%) Rate per TTY
1 (0.01) 0.16
4 (0.05) 0.64
4 (0.05) 0.64
9 (0.10) 1.43 0.70 (0.21e2.30)
risk ratio TTYZ 1000 treatment years.
ance and reliever therapy versus comparators.
Figure 2 Forest-plots of ManteleHaenszel relative risks for primary outcome events. CI Z confidence interval; RR Z risk ratio;
SAE Z serious adverse event.
Safety of symbicort maintenance and reliever therapy 1965of events became too low for any meaningful comparisons
to be made. For the co-primary endpoint, asthma-related
SAEs, all four comparisons gave results favouring budeso-
nide/formoterol maintenance and reliever therapy, with
reductions ranging from 28% (versus budesonide/formoterol
plus formoterol as needed) to 50% (versus budesonide plus
SABA as needed). The results are presented in Tables E3eE6
in the on-line supplement.
Results in patients aged 50 years and older
Among the 4347 subjects aged 50 years and older, findings
were similar to those for the whole study population (Table
E7 in the on-line supplement).
Results from open-label trials
As a supplementary analysis, we analysed data from seven
open-label trials.16,23 In these trials, 4963 patients treated
with budesonide/formoterol maintenance and reliever
therapy (total exposure 2.9 TTY) were compared with
patients treated with salmeterol/fluticasone plus SABA asTable 3 Asthma-related and cardiac-related serious adverse e
randomised controlled trials
BUD/FORM maintenance and relieve
therapy: NZ 5584; exposureZ 3.94
Na (%)
Asthma-related SAEs 41 (0.73)
Cardiac-related SAEs 23 (0.41)
Patients with any SAE 233 (4.17)
Asthma-related DAEs 25 (0.45)
Cardiac-related DAEs 8 (0.14)
Patients with any DAE 75 (1.34)
BUD/FORMZ budesonide/formoterol; CIZconfidence interval; DA
SAEZ serious adverse event; TTYZ 1000 treatment years.
a Number of patients reporting at least one SAE or number of patie
b ManteleHaenszel relative risk for budesonide/formoterol maintenneeded (nZ 1071; 1.0 TTY) or conventional best practice,
as judged by the investigator (nZ 3856; 1.9 TTY). There
were four deaths with budesonide/formoterol maintenance
and reliever therapy versus five deaths with comparator
treatments, none of which were asthma-related. Asthma-
related SAEs were numerically lower among patients
treated with budesonide/formoterol maintenance and
reliever therapy (nZ 24; 0.49%) than among those treated
with the comparators (nZ 32; 0.65%) (Table E8 in the on-
line supplement).
Discussion and conclusions
In this trial database of 14 346 patients participating in
randomised, double-blind, controlled trials, the number of
all-cause deaths and asthma-related SAEs (the two co-
primary endpoints) were lower among patients who
received budesonide/formoterol maintenance and reliever
therapy compared with those who received alternative
treatments. The risks for asthma-related SAEs and DAEs
and overall DAEs were significantly reduced by budesonide/
formoterol maintenance and reliever therapy (by 41%, 57%vents and discontinuations due to adverse events across six
r
TTY
Comparators: NZ 8762;
exposureZ 6.29 TTY
RR (95% CI)b
Na (%)
121 (1.38) 0.59 (0.42e0.85)
27 (0.31) 1.26 (0.72e2.22)
392 (4.47) 0.96 (0.82e1.14)
85 (0.97) 0.43 (0.28e0.68)
15 (0.17) 0.73 (0.30e1.73)
183 (2.09) 0.60 (0.46e0.79)
EZdiscontinuation due to adverse event; RRZrisk ratio;
nts reporting DAE.
ance and reliever therapy versus comparators.
Figure 3 KaplaneMeier survival curves showing time to first
asthma-related serious adverse event.
1966 M.R. Sears, F. Radnerand 40%, respectively) and the time to the first asthma-
related SAE was increased by 41%. The risks for cardiac-
related DAEs and SAEs and overall SAEs were similar
between the two treatment groups. It is important to note
that all but one of the comparator arms constitute stan-
dard treatments for patients with moderate to severe
asthma, the exception being the formoterol/budesonide
maintenance plus formoterol as needed arm in the trial by
Rabe et al.12
These results demonstrate that the increased efficacy
repeatedly shown for budesonide/formoterol maintenance
and reliever therapy is not associated with any decrease inFigure 4 Forest-plots of ManteleHaenszel relative risks fo
DAE Z discontinuation due to adverse event; RR Z risk ratio; SAEthe safety of the treated patients, but rather the opposite.
This new treatment regimen, with occasional use of high
doses of ICS, was not associated with any increase in
possible ICS-mediated adverse events in the budesonide/
formoterol maintenance and reliever therapy group. Also,
the rate of common b2-agonist side effects was not
increased following the use of formoterol as needed.
The ongoing debate on the safety of LABAs with respect
to asthma mortality and morbidity originates largely from
post-marketing surveillance trials with salmeterol, most
recently the Salmeterol Multicentre Asthma Research Trial
(SMART),24 and subsequent meta-analyses20 heavily influ-
enced by that study. SMART showed an increased risk of
asthma mortality in the LABA group (2.0 versus 0.5 asthma
deaths per TTY in the LABA and placebo groups, respec-
tively). However, only 47% of the patients were reported to
have been prescribed ICS at baseline. Large pooled analyses
by Sears et al. of over 68 000 asthmatic patients involved in
AstraZeneca clinical trials with formoterol-containing
products25 (92% ICS users) and by Jaeschke et al. of 29 000
patients enrolled in trials with salmeterol plus ICS or for-
moterol plus ICS versus ICS alone19 (100% ICS users) showed
low rates of asthma mortality but, because of the low
number of asthma-related deaths, no definite conclusions
could be drawn.
The observations in the current analysis, relating to
a new treatment strategy specific to the budesonide/for-
moterol combination, do not add data directly applicable
to this LABA safety debate since the main analysis does not
involve a direct LABA versus non-LABA comparison.
However, we can state that the observed rate of asthma-
related death in the budesonide/formoterol maintenancer secondary outcome events. CI Z confidence interval;
Z serious adverse event.
Table 4 Incidence of b2-agonist- or inhaled corticoste-
roid-related adverse events of interest (serious and non-
serious).
Preferred term Number (%) of patients reporting at
least one adverse event
BUD/FORM maintenance
and reliever therapy
NZ 5584
Comparators
NZ 8762
Dysphonia 61 (1.1) 91 (1.0)
Oral candidiasis 58 (1.0) 69 (0.8)
Tremor 33 (0.6) 67 (0.8)
Palpitations 34 (0.6) 37 (0.4)
Pneumoniaa 33 (0.6) 68 (0.8)
Cataract 3 (0.05) 4 (0.05)
Glaucoma 4 (0.07) 3 (0.03)
BUD/FORMZ budesonide/formoterol.
a Pneumonia has been included for completeness due to the
current debate on the relationship between pneumonia and
inhaled corticosteroids in chronic obstructive pulmonary
disease.
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Safety of symbicort maintenance and reliever therapy 1967and reliever therapy group (100% ICS users) of one death in
3930 treatment years (rate 0.25 deaths per TTY) was low. In
addition, it can be noted that in seven open-label trials
(Vogelmeier et al.23 plus six pooled trials with conventional
best practice as comparator16) no asthma-related deaths
were reported in over 4900 patients exposed to budeso-
nide/formoterol maintenance and reliever therapy during
over 2900 years of exposure. Furthermore, among these
open-label trials, which bear a closer resemblance than
double-blind trials to the real-world setting, asthma-
related SAEs were numerically lower among patients
treated with budesonide/formoterol maintenance and
reliever therapy than among those on standard asthma
treatments. Nevertheless, despite these reassuring find-
ings, it is recognised that patients with significant co-
morbidities are generally excluded from all of these trials,
and ongoing pharmacovigilance with post-marketing
surveillance is appropriate.
Our findings are consistent with other recent safety
analyses of ICS/LABA combinations, which have concluded
that adding a LABA to ICS is both effective and safe for the
treatment of asthma,26e29 and that the risk of asthma-
related SAEs (mainly hospitalisations due to asthma) was
lowered in the ICS/LABA groups compared with treatment
with ICS alone.25 The use of LABA in combination with an
appropriate dose of ICS is consistent with recommendations
in international guidelines and the labels approved by most
regulatory authorities.
Treatment with budesonide/formoterol maintenance
and reliever therapy has consistently shown similar or
better current control and reduced future risk of exacer-
bations compared with guideline-recommended fixed-dose
comparators. This has been achieved at a lower overall
exposure to oral and systemic corticosteroids.6,8e12 This
analysis has addressed another component of future risk,
namely medication adverse events.
Budesonide/formoterol maintenance and reliever
therapy has been shown to be well tolerated and not
associated with increased safety concerns, with lower orsimilar incidence of death and asthma-related SAEs
compared with the fixed-dose comparators. These results
also demonstrate that occasional use of high doses of for-
moterol, taken as needed at times of deteriorating asthma
symptoms, delivered together with budesonide, does not
increase the rate of asthma-related events but instead
significantly lowers the risk. This is of particular impor-
tance, since one of the hypotheses for the potential risk of
LABAs in asthma is that treatment with LABAs would cause
b2-receptor desensitisation and subsequent lack of
response to bronchodilator therapy in emergency situa-
tions.30 In this large clinical database there is no support for
this hypothesis.
We conclude that the budesonide/formoterol mainte-
nance and reliever therapy regimen3 in randomised clinical
trials is not associated with increased risk of cardiac- or
asthma-related deaths or SAEs and is well tolerated, with
anticipated class-related adverse events due to b2-agonists
or ICS. Compared with present fixed-dose alternatives, this
strategy offers at least as good reduction of future risk of
medication adverse events.Acknowledgements
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